Israeli Pharma gets FDA Approval for New Antibody against Severe Asthma

25/03/2016 - 3 minutes

Teva (Israel) can now commercialize their intravenous drug (Cinqair) in the US, which will help adults with severe asthma.  

teva_reslizumab_severe_asthma_cinqairBased near Tel Aviv, Teva is the largest producer of generics, but it is also conducting its own biotech research. These include collaborations with Active Biotech (Sweden) for treatment of Huntington’s disease, and Heptares Therapeutics (UK) for a novel small molevule against migraines.

Teva can now beef up its sales with a new drug from its own pipeline, as reslizumab (Cinqair) has received marketing approval from the FDA.

This treatment will be available for adult patients with severe asthma showing an eosinophilic phenotype – types of asthma in which the patients have high count of this type of white blood cell.  This type is associated with more frequent symptoms and a higher risk of asthma attacks.

Reslizumab is a monoclonal antibody that binds interleukin-5, having an antagonistic effect.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member